Clinical Trial · NCT07587814

Impact of Body Composition on Dosimetry of 177Lu-PSMA Radioligand Therapy

Overview

COCORIVO is an interventional study evaluating the impact of body composition on dosimetry of 177Lu-PSMA radioligand therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Body composition (muscle, lean, visceral fat, subcutaneous fat and total fat masses) will be automatically quantified from whole-body CT images acquired at 72-96h after 177Lu-PSMA injection using the Anthropometer3DNet software. Dosimetry will be evaluated for tumors and organs at risk (salivary glands, bone marrow, kidneys). The study also evaluates the impact of body composition on SUV quantification, the feasibility of single-timepoint dosimetry, and the evolution of body composition during treatment.

Sponsor

Centre Henri Becquerel

Phase

N/A

Contacts

Doriane Richard, PhD (CONTACT)

doriane.richard@chb.unicancer.fr

+33 2 32 08 29 85

Pierre Decazes, MD, PhD (CONTACT)

pierre.decazes@chb.unicancer.fr

+33 2 76 67 30 59

ClinicalTrials.gov

NCT07587814

Drug / Compound

PSMA-617

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: DOTA

Eligibility

Inclusion

Histologically confirmed prostatic adenocarcinoma with multidisciplinary decision for 177Lu-PSMA treatment
PSMA expression in tumor lesions confirmed by 68Ga-PSMA PET/CT

Exclusion

Exclusion criteria not yet provided.